S-CUD

Not yet recruitingPhase 2

Semaglutide for the Treatment of Cannabis Use Disorder

Lead sponsor

Massachusetts General Hospital

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

Study population

Alcohol / substance use

Eligibility highlights

Primary endpoints

•Cannabis cue-reactivity•Resting state connectivity

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07879612

Org study ID2026P002063

Timeline

Milestones

Study first posted2026-10-19actual

Last update posted2026-10-19actual

Study start2027-01-10estimated

Primary completion2029-01-30estimated

Study completion2029-03-30estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Alcohol / substance use

Who can enroll

Minimum age18 Years

Maximum age60 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Adults aged 18-60 years, inclusive;

•Use cannabis daily or near daily and have been using cannabis consistently for at least the past year, by self-report;

•Diagnosed with moderate to severe DSM-5 cannabis use disorder

•Access to a mobile device to complete daily surveys

•Desire to quit or reduce cannabis consumption

•Be able to read, speak, and understand the English language. English can be a second language provided that the subject understands all the questions used in the assessment measures.

Exclusion criteria

•Active psychosis, active suicidality (current suicidal ideation with specific plan or intent) or homicidality, suicide attempt or psychiatric hospitalization in the past year, or any psychiatric condition that may impair ability to provide informed consent.

•Any current or lifetime diagnosis of eating disorders including anorexia, bulimia, or binge eating;

•Any current substance use disorder other than cannabis or mild alcohol use disorder;

•BMI <21 kg/m2;

•MRI contraindications (including presence of metallic foreign bodies such as cardiac pacemakers, perfusion pumps, aneurysm clips, metallic tattoos anywhere on the body, tattoos near the eye);

•Current or lifetime diagnosis of Type 1 or Type 2 diabetes;

•Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2;

•Use of any GLP-1 agonist medications in the prior 3 months;

•Anticipating use of any other GLP-1 agonist medications during the trial;

•Current hypoglycemia as indicated by a blood sugar level of <71 mg/dL measured at baseline visit;

•Untreated cholelithiasis or gallbladder disease;

•History of acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, or congestive heart failure in the last year;

•Systolic blood pressure persistently above 160mmHg or diastolic blood pressure persistently above 100mmHg during screening;

•History of inflammatory bowel disease, bariatric surgery, pancreatitis, diabetic gastroparesis, or non-arteritic anterior ischemic optic neuropathy;

•Liver function test greater than 3 times upper normal limit at baseline;

•Renal impairment as indicated by eGFR of <30;

•History of hypersensitivity or allergy to semaglutide;

•Pregnant or breastfeeding;

•Currently taking GLP-1 agonists or other weight loss drugs;

•Anticipated to participate in a concurrent drug trial;

•Anticipating to undergo elective surgeries or procedure requiring general anesthesia during duration of the study;

•Any other reason or clinical condition that the investigators judge may interfere with study participation and/or be unsafe for a participant.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

Cannabis cue-reactivity

Time frame:Baseline (pre-intervention), 8 weeks

descriptive

Primary/protocol endpoint/low confidence

Resting state connectivity

Time frame:Baseline (pre-intervention), 8 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.